Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
University of Texas, M. D. Anderson Cancer Center publishes research in cancer gene therapy
December 23rd, 2008
Research findings, 'Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer,' are discussed in a new report. According to a study from the United States, "Preclinical data showed enhancement of breast cancer cell death when G3139 was combined with anthracyclines and taxanes. We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)." "Following a brief phase I to determine the phase II dose, patients with locally advanced breast cancer received G3139 administered by...
Source: Cancer Weekly (2008-12-23)
|
